The COVID-19 pandemic has put a damper on the FDA’s on-site inspections in 2020, but that doesn’t mean the agency isn’t making the rounds and putting drugmakers on notice. A second U.S. company making prescription thyroid meds is on the receiving end of FDA’s ire this year for potency concerns.
FDA investigators cited Phoenix-based RLC Labs for failing to adequately address a host of quality-control issues that led to the recall of 483 lots of two of the company’s thyroid meds, according to a warning letter posted online Tuesday.
